(Verbatim from the Applicant): Recent evidence indicates that extracellular calcium plays a physiological role in modulating bone remodeling through putative calcium sensing G-protein coupled receptors in osteoblasts and osteoclasts. The osteoblastic cation sensing receptor(s) may be pharmacologic targets for the induction of de novo bone formation. There is controversy, however, regarding whether the prototypic calcium receptor, CasR, or another receptor transduces these skeletal responses to calcium and other cations. We have evidence for a novel cation-sensing receptor in osteoblasts, ObCasR, that regulates osteoblast proliferative responses underlying cation-induced de novo bone formation. The existence of ObCasR is supported by the presence of a cation sensing response in osteoblasts from CasR knock-out mice, and by differences between ObCasR and CasR with regards to cell-type expression, G-protein coupling, and ligand specificity. Nevertheless, we identified a bone phenotype in CasR knock-out mice that could be attributed to either excess PTH, or lose of CasR in bone. Thus, the relative importance of CasR and ObCasR in the skeleton remains to be defined. Our overall goal is to define the skeletal function of ObCasR and CasR. We will advance the hypothesis that another cation sensing CasR-like receptor plays an important regulatory role in osteoblast-mediated bone formation by completing our characterization and cloning of ObCasR. Specific studies will: (1) investigate and compare Galpha subtype specificity and signal transduction pathways of ObCasR and CasR; (2) expression clone ObCasR by screening an osteoblast CDNA library for the extracellular cation sensing receptor(s) positively coupled to serum response element (SR-E)-mediated gene transcription; and (3) examine the function of CasR in the skeleton in CasR knock-out mice (CasR -/-) after removing the confounding effect of hyperparathyroidism by transgenic rescue of CasR deficiency in the parathyroid glands or ablation of the parathyroid glands. Defining the presence and function of cation sensing receptors in bone will permit a better understanding of physiologic and pharmacologic control of de novo bone formation by cations that may lead to new therapies for osteopenic disorders.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Research Project (R01)
Project #
7R01AR037308-17
Application #
6936748
Study Section
Special Emphasis Panel (ZRG1-ORTH (01))
Program Officer
Sharrock, William J
Project Start
1986-08-01
Project End
2005-12-31
Budget Start
2004-05-15
Budget End
2004-12-31
Support Year
17
Fiscal Year
2004
Total Cost
$285,915
Indirect Cost
Name
University of Kansas
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
016060860
City
Kansas City
State
KS
Country
United States
Zip Code
66160
Pi, Min; Kapoor, Karan; Ye, Ruisong et al. (2018) GPCR6A Is a Molecular Target for the Natural Products Gallate and EGCG in Green Tea. Mol Nutr Food Res 62:e1700770
Xiao, Zhousheng; Baudry, Jerome; Cao, Li et al. (2018) Polycystin-1 interacts with TAZ to stimulate osteoblastogenesis and inhibit adipogenesis. J Clin Invest 128:157-174
Ye, Ruisong; Pi, Min; Cox, John V et al. (2017) CRISPR/Cas9 targeting of GPRC6A suppresses prostate cancer tumorigenesis in a human xenograft model. J Exp Clin Cancer Res 36:90
Pi, Min; Kapoor, Karan; Ye, Ruisong et al. (2016) Evidence for Osteocalcin Binding and Activation of GPRC6A in ?-Cells. Endocrinology 157:1866-80
Pi, Min; Kapoor, Karan; Wu, Yunpeng et al. (2015) Structural and Functional Evidence for Testosterone Activation of GPRC6A in Peripheral Tissues. Mol Endocrinol 29:1759-73
Pi, Min; Quarles, L Darryl (2012) GPRC6A regulates prostate cancer progression. Prostate 72:399-409
Pi, Min; Quarles, L Darryl (2012) Multiligand specificity and wide tissue expression of GPRC6A reveals new endocrine networks. Endocrinology 153:2062-9
Dreaden, Erik C; Gryder, Berkley E; Austin, Lauren A et al. (2012) Antiandrogen gold nanoparticles dual-target and overcome treatment resistance in hormone-insensitive prostate cancer cells. Bioconjug Chem 23:1507-12
Pi, Min; Wu, Yunpeng; Lenchik, Nataliya I et al. (2012) GPRC6A mediates the effects of L-arginine on insulin secretion in mouse pancreatic islets. Endocrinology 153:4608-15
Pi, Min; Wu, Yunpeng; Quarles, L Darryl (2011) GPRC6A mediates responses to osteocalcin in ?-cells in vitro and pancreas in vivo. J Bone Miner Res 26:1680-3

Showing the most recent 10 out of 57 publications